Results for tag: "Non Muscle Invasive Bladder Cancer"

Non Muscle Invasive Bladder Cancer (NMIBC) is a subset of bladder cancer where the disease is limited to the mucosal surface and the submucosa of the bladder wall, not penetrating into the muscle layer. As part of the broader field of oncology, NMIBC is distinct due to its treatment modalities, which often include intravesical therapy (direct injection of therapeutic agents into the bladder), transurethral resection, and in some cases, immunotherapy or chemotherapy. Surveillance is critical in managing NMIBC due to the high rate of recurrence and progression to muscle-invasive stages of the disease. Research in NMIBC is focused on improving diagnostic techniques, developing more effective intravesical treatments, reducing recurrence rates, and enhancing quality of life for patients. Some notable companies involved in the NMIBC market are Merck & Co., which provides immunotherapeutic agents for treating this form of bladder cancer; BCG Oncology, known for its Bacillus Calmette-Guerin based treatments; UroGen Pharma, with its focus on uro-oncology and treatments directly applicable to the urinary tract; AstraZeneca, boasting a diverse oncology portfolio including treatments relevant to bladder cancer; and Photocure, which specializes in photodynamic therapies designed to target bladder cancer cells. These companies play instrumental roles in the development of new treatment protocols and medication regimes to manage NMIBC. Show Less Read more